{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:52:19Z","timestamp":1791535939919,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T00:00:00Z","timestamp":1324512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T00:00:00Z","timestamp":1324512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                        <jats:title>Introduction\n<\/jats:title>\n                        <jats:p>The prevalence of antibodies to RNA polymerase III (anti-RNAP) differs among systemic sclerosis (SSc) cohorts worldwide. Previously reported associations of anti-RNAP include diffuse cutaneous disease, tendon friction rubs and renal crisis, with recent reports suggesting a close temporal association between malignancy and SSc disease onset among patients with anti-RNAP.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods\n<\/jats:title>\n                        <jats:p>Patients with SSc were tested for the presence of anti-RNAP at recruitment into the Australian Scleroderma Cohort Study. We used univariate and multivariable methods to identify and quantify clinical and laboratory correlates of anti-RNAP in SSc. Diagnostic testing procedures were used to determine the usefulness of these antibodies in estimating the likelihood of clinically important outcomes.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results\n<\/jats:title>\n                        <jats:p>There were 451 patients with mean \u00b1 standard deviation age and disease duration at recruitment of 58.1 \u00b1 12.4 and 11.6 \u00b1 10.0 years, respectively; 151 (33.5%) patients were recruited within 5 years of diagnosis of SSc. Overall, 69 (15.3%) patients had anti-RNAP. Univariate associations of anti-RNAP were diffuse disease (75.4% vs. 20.9%, <jats:italic>P<\/jats:italic> &lt; 0.0001), joint contractures (73.9% vs. 30.1%, <jats:italic>P<\/jats:italic> &lt; 0.0001), greater highest-recorded modified Rodnan skin score (20.6 \u00b1 12.4 vs. 10.1 \u00b1 7.9, <jats:italic>P<\/jats:italic> &lt; 0.0001), synovitis (31.9% vs. 19.9%, <jats:italic>P<\/jats:italic> = 0.03), myositis (2.9% vs. 0.5%, <jats:italic>P<\/jats:italic> = 0.05), systemic hypertension (59.4% vs. 39.7%, <jats:italic>P<\/jats:italic> = 0.002), renal crisis (24.6% vs. 1.8%, <jats:italic>P<\/jats:italic> &lt; 0.0001) and malignancy diagnosed within 5 years of onset of SSc skin disease (13.3% vs. 3.9%, <jats:italic>P<\/jats:italic> = 0.01). In multiple regression analysis, after adjustment for other covariates, anti-RNAP were independently associated with renal crisis (odds ratio (OR) 3.8, 95% confidence interval (CI) 1.2 to 11.5, <jats:italic>P<\/jats:italic> = 0.02; positive predictive value (PPV) 24.6%, negative predictive value (NPV) 98.2%), diffuse disease (OR 6.4, 95% CI 2.9 to 13.8, <jats:italic>P<\/jats:italic> &lt; 0.0001; PPV 75.4%, NPV 20.9%), joint contractures (OR 2.5, 95% CI 1.2 to 5.3, <jats:italic>P<\/jats:italic> = 0.02; PPV 73.9%, NPV 69.9%) and malignancy diagnosed within 5 years of onset of SSc skin disease (OR 4.2, 95% CI 1.3 to 13.4, <jats:italic>P<\/jats:italic> = 0.01; PPV 13.3%, NPV 96.1%).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions\n<\/jats:title>\n                        <jats:p>Anti-RNAP status is a clinically useful prognostic marker in SSc and enables clinicians to identify patients at high risk of developing renal crisis, synovitis, myositis and joint contractures. Patients with anti-RNAP also have an increased risk of malignancy within a 5-year timeframe before or after onset of SSc skin changes.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar3544","type":"journal-article","created":{"date-parts":[[2012,1,24]],"date-time":"2012-01-24T19:46:37Z","timestamp":1327434397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort"],"prefix":"10.1186","volume":"13","author":[{"given":"Mandana","family":"Nikpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Hissaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Byron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Sahhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Paspaliaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Sturgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,22]]},"reference":[{"key":"3293_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.berh.2010.10.007","volume":"24","author":"M Nikpour","year":"2010","unstructured":"Nikpour M, Stevens WM, Herrick AL, Proudman SM: Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol. 2010, 24: 857-869. 10.1016\/j.berh.2010.10.007.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3293_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.7326\/0003-4819-119-10-199311150-00007","volume":"119","author":"Y Okano","year":"1993","unstructured":"Okano Y, Steen VD, Medsger TA: TextAutoantibody reactive with RNA polymerase III in systemic sclerosis. Annals Internal Med. 1993, 119: 1005-1013.","journal-title":"Annals Internal Med"},{"key":"3293_CR3","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/art.10521","volume":"46","author":"M Kuwana","year":"2002","unstructured":"Kuwana M, Kimura K, Kawakami Y: Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum. 2002, 46: 2742-2747. 10.1002\/art.10521.","journal-title":"Arthritis Rheum"},{"key":"3293_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/rheumatology\/kep215","volume":"48","author":"SI Nihtyanova","year":"2009","unstructured":"Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP: A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology. 2009, 48: 1218-1221. 10.1093\/rheumatology\/kep215.","journal-title":"Rheumatology"},{"key":"3293_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejim.2010.01.004","volume":"21","author":"B Faucher","year":"2010","unstructured":"Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harle JR, Durand JM, Frances Y, Guis S, Pham T, Bardin N, Sanmarco M: Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma. Eur J Internal Med. 2010, 21: 114-117. 10.1016\/j.ejim.2010.01.004.","journal-title":"Eur J Internal Med"},{"key":"3293_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3899\/jrheum.090677","volume":"37","author":"O Meyer","year":"2010","unstructured":"Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, Hayem G, Palazzo E, Chollet-Martin S, Kahan A, Allanore Y: Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol. 2010, 37: 125-130. 10.3899\/jrheum.090677.","journal-title":"J Rheumatol"},{"key":"3293_CR7","first-page":"104","volume":"34","author":"OC Meyer","year":"2007","unstructured":"Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA: Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol. 2007, 34: 104-109.","journal-title":"J Rheumatol"},{"key":"3293_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/37.1.15","volume":"37","author":"CC Bunn","year":"1998","unstructured":"Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM: Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol. 1998, 37: 15-20. 10.1093\/rheumatology\/37.1.15.","journal-title":"Br J Rheumatol"},{"key":"3293_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","volume":"158","author":"Y Hamaguchi","year":"2008","unstructured":"Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, Kondo M, Nishijima C, Hayakawa I, Ogawa F, Kuwana M, Takehara K, Sato S: The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol. 2008, 158: 487-495. 10.1111\/j.1365-2133.2007.08392.x.","journal-title":"Br J Dermatol"},{"key":"3293_CR10","first-page":"1528","volume":"34","author":"M Santiago","year":"2007","unstructured":"Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ: Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol. 2007, 34: 1528-1534.","journal-title":"J Rheumatol"},{"key":"3293_CR11","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1002\/art.21232","volume":"52","author":"M Kuwana","year":"2005","unstructured":"Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA: Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005, 52: 2425-2432. 10.1002\/art.21232.","journal-title":"Arthritis Rheum"},{"key":"3293_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","volume":"100","author":"H Penn","year":"2007","unstructured":"Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A, Denton CP: Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007, 100: 485-494. 10.1093\/qjmed\/hcm052.","journal-title":"QJM"},{"key":"3293_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","volume":"48","author":"T Satoh","year":"2009","unstructured":"Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M: Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology. 2009, 48: 1570-1574. 10.1093\/rheumatology\/kep290.","journal-title":"Rheumatology"},{"key":"3293_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3899\/jrheum.101144","volume":"38","author":"P Airo","year":"2011","unstructured":"Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F: Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol. 2011, 38: 1329-1334. 10.3899\/jrheum.101144.","journal-title":"J Rheumatol"},{"key":"3293_CR15","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/art.27549","volume":"62","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L: Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum. 2010, 62: 2787-2795. 10.1002\/art.27549.","journal-title":"Arthritis Rheum"},{"key":"3293_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980): Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheumatism. 1980, 23: 581-590. 10.1002\/art.1780230510.","journal-title":"Arthritis Rheumatism"},{"key":"3293_CR17","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA: Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001, 28: 1573-1576.","journal-title":"J Rheumatol"},{"key":"3293_CR18","first-page":"1281","volume":"22","author":"P Clements","year":"1995","unstructured":"Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995, 22: 1281-1285.","journal-title":"J Rheumatol"},{"key":"3293_CR19","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3899\/jrheum.080340","volume":"35","author":"Y Hamaguchi","year":"2008","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S: Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol. 2008, 35: 2363-2371. 10.3899\/jrheum.080340.","journal-title":"J Rheumatol"},{"key":"3293_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-010-0145-7","volume":"13","author":"G Bussone","year":"2011","unstructured":"Bussone G, Berezne A, Pestre V, Guillevin L, Mouthon L: The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. 2011, 13: 37-43. 10.1007\/s11926-010-0145-7.","journal-title":"Curr Rheumatol Rep"},{"key":"3293_CR21","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","volume":"44","author":"VD Steen","year":"2001","unstructured":"Steen VD, Medsger TA: Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001, 44: 2828-2835. 10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U.","journal-title":"Arthritis Rheum"},{"key":"3293_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-0-387-77574-6_8","volume":"624","author":"U Leiter","year":"2008","unstructured":"Leiter U, Garbe C: Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol. 2008, 624: 89-103. 10.1007\/978-0-387-77574-6_8.","journal-title":"Adv Exp Med Biol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3544\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3544.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:25:37Z","timestamp":1728383137000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,22]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,12]]}},"alternative-id":["3293"],"URL":"https:\/\/doi.org\/10.1186\/ar3544","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,22]]},"assertion":[{"value":"2 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R211"}}